Gusacitinib shows promise as treatment for chronic hand eczema

Gusacitinib significantly outperformed placebo, showing a tolerable safety profile and a rapid improvement in the treatment of patients with chronic hand eczema, according to a phase 2 study.“Chronic hand eczema (CHE) current treatment options are limited and there is a high medical need for new options,” Pablo A. Jimenez, MD, FAPCR, chief medical officer and senior vice president of

Related Keywords

Pabloa Jimenez , Libertas Biosciences , , Global Assessment , Asana Biosciences , Total Lesion Symptom Score , Patient Global Assessment , Physician Global Assessment ,